Source comparison
CJC-1295 Formulation and Dosing Comparison
| Formulation | Half-Life | Optimal Dose Range | Injection Frequency | Pulsatility Preservation | Receptor Sensitivity Risk | Bottom Line ||—|—|—|—|—|—|| CJC-1295 with DAC | 6–8 days | 100–200mcg | Twice weekly | Low. Sustains tonic elevation | Moderate to hig
This comparison does not assign a generated winner or score.
- | Formulation | Half-Life | Optimal Dose Range | Injection Frequency | Pulsatility Preservation | Receptor Sensitivity Risk | Bottom Line ||—|—|—|—|—|—|| CJC-1295 with DAC | 6–8 days | 100–200mcg | Twice weekly | Low. Sustains tonic elevation | Moderate to high with chronic use | Best for convenience-focused protocols; higher desensitisation risk beyond 12 weeks || CJC-1295 without DAC | ~30 minutes | 100mcg | 1–3 times daily | High. Amplifies natural pulses | Low. Discrete dosing allows receptor recovery | Best for long-term protocols prioritising physiological rhythm; requires more frequent administration || CJC-1295 + Ipamorelin Stack | Varies by component | 100mcg CJC + 100–200mcg ipamorelin | Daily (non-DAC) or twice weekly (DAC) | Moderate. Dual pathway reduces single-receptor burden | Low. Ghrelin pathway provides alternative stimulation | Best for maximising GH output while minimising receptor fatigue; most complex to source and administer |